Nurix Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Nurix Therapeutics, Inc. on May 15, 2026. The meeting was conducted exclusively via live webcast. As of the record date of March 20, 2026, 83,747,013 shares of common stock were present, representing approximately 80.98% of the voting power, which constituted a quorum.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on corporate governance voting results and does not contain financial performance data.
Material Changes and Voting Results
Stockholders voted on three proposals, all of which were approved:
- Proposal 1 (Election of Directors): Three Class III directors were elected to serve three-year terms expiring in 2029.
- Arthur T. Sands, M.D., Ph.D.: 63,592,948 votes for; 16,334,570 votes withheld.
- Roger Dansey, M.D.: 79,607,489 votes for; 320,029 votes withheld.
- Paul M. Silva: 59,298,612 votes for; 20,628,906 votes withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending November 30, 2026.
- Votes For: 83,555,977
- Votes Against: 166,391
- Abstentions: 24,645
- Proposal 3 (Executive Compensation): Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers.
- Votes For: 72,458,920
- Votes Against: 6,895,394
- Abstentions: 573,204
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the reporting of voting outcomes.
Key Facts for Investor Verification
- Verify the specific terms of the three-year directorships for the newly elected Class III directors.
- Confirm the scope of the audit engagement with PricewaterhouseCoopers LLP for the fiscal year ending November 30, 2026.
- Review the definitive proxy statement filed on March 27, 2026, for detailed executive compensation data referenced in Proposal 3.
- Note that the filing contains no financial performance metrics; refer to the most recent 10-K or 10-Q for financial status.